NCT00842192View on ClinicalTrials.gov

An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries

CompletedOBSERVATIONAL
Enrollment

2,155

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin detemir

Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.

Trial Locations (4)

11844

Novo Nordisk Investigational Site, Amman

Novo Nordisk Investigational Site, Amman

44425

Novo Nordisk Investigational Site, Kfar Saba

Unknown

Novo Nordisk Investigational Site, Karachi

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00842192 - An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries | Biotech Hunter | Biotech Hunter